This article is part of a Chronicle. See more from this Chronicle
Michael Frese, Ingrid Vandenborre, Julia York, Nov 24, 2014
In recent years, courts in both the United States and the European Union have increasingly been asked to consider under what circumstances the introduction of a new pharmaceutical drug product harms, rather than benefits, competition in contravention of the antitrust and competition laws. In the European Union, antitrust regulators have been active in challenging so-calle
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.97.14.85
Please verify email or join us to access premium content!